Fractyl Health, Inc. (NASDAQ:GUTS) Receives $7.40 Consensus Price Target from Brokerages

Fractyl Health, Inc. (NASDAQ:GUTS) has earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $7.40.

A number of equities analysts recently issued reports on GUTS shares. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Friday, December 19th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Tuesday, December 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Fractyl Health in the 2nd quarter worth about $26,000. Jane Street Group LLC bought a new stake in Fractyl Health during the second quarter worth about $31,000. FNY Investment Advisers LLC purchased a new stake in Fractyl Health in the third quarter worth about $31,000. Scientech Research LLC purchased a new stake in Fractyl Health in the third quarter worth about $49,000. Finally, Prelude Capital Management LLC bought a new position in shares of Fractyl Health during the third quarter valued at approximately $55,000.

Fractyl Health Stock Up 0.5%

Shares of GUTS stock opened at $2.01 on Friday. The firm has a market capitalization of $275.45 million, a price-to-earnings ratio of -0.88 and a beta of 1.62. The stock has a fifty day moving average of $1.84 and a 200 day moving average of $1.50. Fractyl Health has a 52 week low of $0.82 and a 52 week high of $3.03.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Equities research analysts anticipate that Fractyl Health will post -1.61 earnings per share for the current year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.